Global Biologics CDMO Manufacturing Network

The global Just – Evotec Biologics network includes two US-based and one EU-based site, offering biotherapeutics discovery, cell line, analytical, process development capabilities as well as early clinical to commercial cGMP biomanufacturing.

Furthermore, we can leverage the whole Evotec network globally to support integrated or complementary antibody/biologics activities and benefit from therapeutic area experts’ input.

Just - Evotec Biologics manufactures biotherapeutics for our partners from three locations.

  • J.PLANT Seattle, US: Smaller-scale manufacturing for early-phase clinical supply
  • J.POD Redmond, US: Capable of Phase I through to Commercial-scale production
  • J.POD Toulouse, EU: Capable of Phase I through to Commercial-scale production

All three sites offer process development and manufacturing capabilities under one roof. Our J.POD facilities are our flagship manufacturing sites. Each J.POD is capable of delivering up to and beyond 2,000 kg per year of biologic drug substance each.

The J.POD facility design and our standardized platform are enabling us to seamlessly transfer work around the globe... We can be manufacturing late-phase clinical material at our J.POD in the US, and then quickly transfer that process for commercialization to the J.POD facility in France.
Kevin Ingham, Manufacturing Operations and Site Head, Redmond, US

Our J.PODs in a Nutshell

  • Agile Manufacturing Solutions:  J.POD introduces next-generation manufacturing solutions with its unique facility design, built around Just – Evotec Biologics’ leading continuous manufacturing technology.
  • Modular Cleanrooms for Efficient Bioprocessing:  J.PODs incorporate modular cleanrooms for intensified bioprocessing, reducing manufacturing space and overall plant size.
  • Integrated PD Labs:  J.PODs house integrated Process Development (PD) labs, streamlining the development and manufacturing process.
  • Versatile and Cost-Efficient:  J.PODs utilize disposable technologies and intensified processes, creating flexible and relatively low-cost biomanufacturing facilities.
  • Seamless Scalability:  J.PODs can accommodate production from a few kilograms to metric tons, providing seamless scalability within the same facility.
  • Faster Setup Time: J.PODs offer significantly faster setup time compared to traditional facilities, enabling rapid response to market demands

Safe Supply Chain Network

Establishing our facilities in geopolitical stable regions is another contributor to our value proposition. 

We want to be close to our partners, offering stable and efficient supply chains. Additionally, we comply with local regulations to meet your quality standards and access US and EU networks and expertise.

Need to secure flexible and low COGS commercial supply chain in a specific geography?

We offer access to commercial capacity within our J.POD facilities network but can also enable strategic Biopharma partners with dedicated J.POD facilities leveraging our proprietary continuous manufacturing technology platform.

As part of our mission to expand global access to patients, we are also ready to enable fast J.POD deployment to face pandemics and explore such strategies with governments and non-profit organizations.

Philip Boehme

Philip Boehme

EVP Partnering & Transformation

vCard
Logo Just white
Just – Evotec Biologics is a mission-driven business unit of Evotec with the aim of radically improving access to biologics through a de-risked, agile approach, coupled with significantly lower manufacturing cost. Over the years we have advanced an industry-transforming bioprocessing platform, which we leverage with our partners to drive what we call the paradigm shift in biologics.